Personalized Medicine May Be Good for Patients But Bad for Drug Companies’ Bottom Line

Personalized, targeted therapies led to Vertex’s Kalydeco breakthrough for cystic fibrosis patients and would allow drugmakers to conduct more concise, targeted clinical trials, says Forbes.
Forbes